Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety ProfileKeyu Li, Bruce A. Keyt, Paul R. Hinton et al.|Blood|2022Cited by 10
Abstract 2959: Novel CD38xCD3 bispecific IgM T cell engager, IGM-2644, potently kills multiple myeloma cells though complement and T cell dependent mechanismsKeyu Li, Bruce A. Keyt, Rui Yun et al.|Cancer Research|2023Cited by 2
Combination of Imvotamab and Loncastuximab Tesirine Shows Enhanced Anti‐Tumor Activity in a Preclinical Model of Non‐Hodgkin’s LymphomaKathryn Logronio, M. F. Kotturi, Mugdha V. Joglekar et al.|Hematological Oncology|2023Cited by 2
Abstract 4179: High valency of IGM-2323, a CD20xCD3 IgM bispecific T cell engager, displaces rituximab binding and induces potent B lymphoma cell killingKevin C. Hart, Maya F. Kotturi, Stephen F. Carroll et al.|Cancer Research|2022Cited by 1